Reason for request
Re-assessment of the actual benefit (AB) and the level of improvement in actual benefit (IAB) at the request of the applicant.
Clinical Benefit
| Low |
The actual benefit of MYOZYME remains low in the treatment of late-onset Pompe disease. |
Clinical Added Value
| minor |
The improvement in actual benefit remains minor (level IV) in the treatment of late-onset Pompe disease. |
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
gkH3zWBAz4skQDbk
Listen
